Pneumococcal Disease and Pneumococcal Vaccines - PowerPoint PPT Presentation

1 / 37
About This Presentation
Title:

Pneumococcal Disease and Pneumococcal Vaccines

Description:

... elderly and very young infants ... of meningitis among children younger than 1 year of ... Persons vaccinated at younger than 65 years of age (at least 5 ... – PowerPoint PPT presentation

Number of Views:451
Avg rating:3.0/5.0
Slides: 38
Provided by: WilliamA6
Category:

less

Transcript and Presenter's Notes

Title: Pneumococcal Disease and Pneumococcal Vaccines


1
  • Pneumococcal Disease and Pneumococcal Vaccines

Epidemiology and Prevention of Vaccine-Preventable
Diseases National Center for Immunization and
Respiratory Diseases Centers for Disease Control
and Prevention
Revised May 2009
2
Note to presenters Images of vaccine-preventable
diseases are available from the Immunization
Action Coalition website at http//www.vaccineinfo
rmation.org/photos/index.asp
3
Pneumococcal Disease
  • S. pneumoniae first isolated by Pasteur in 1881
  • Confused with other causes of pneumonia until
    discovery of Gram stain in 1884
  • More than 80 serotypes described by 1940
  • First U.S. vaccine in 1977

4
Streptococcus pneumoniae
  • Gram-positive bacteria
  • 90 known serotypes
  • Polysaccharide capsule important virulence factor
  • Type-specific antibody is protective

5
Pneumococcal Disease
  • Second most common cause of vaccine-preventable
    death in the U.S. (after influenza)
  • Major clinical syndromes include pneumonia,
    bacteremia, and meningitis

6
Pneumococcal PneumoniaClinical Features
  • Abrupt onset
  • Fever
  • Shaking chills
  • Pleuritic chest pain
  • Productive cough
  • Dyspnea, tachypnea, hypoxia

7
Pneumococcal Pneumonia
  • 100,000 to 135,000 cases requiring
    hospitalization per year
  • Responsible for up to 1/3 of community-acquired
    pneumonias and up to 1/2 of hospital-acquired
    pneumonias
  • Common bacterial complication of influenza and
    measles
  • Case-fatality rate 5-7, higher in elderly

8
Pneumococcal Bacteremia
  • More than 50,000 cases per year in the United
    States
  • Rates higher among elderly and very young infants
  • Case-fatality rate 20 up to 60 among the
    elderly

9
Pneumococcal Meningitis
  • Estimated 3,000 - 6,000 cases per year in the
    United States
  • Case-fatality rate 30, up to 80 in the elderly
  • Neurologic sequelae common among survivors
  • Increased risk in persons with cochlear implant

10
Pneumococcal Disease in Children
  • Bacteremia without known site of infection most
    common clinical presentation
  • S. pneumoniae leading cause of bacterial
    meningitis among children younger than 5 years of
    age
  • Highest rate of meningitis among children younger
    than 1 year of age
  • Common cause of acute otitis media

11
Burden of Pneumococcal Disease in Children
Syndrome Cases
  • Bacteremia 13,000
  • Meningitis 700
  • Death 200
  • Otitis media 5,000,000

Prior to routine use of pneumococcal conjugate
vaccine
12
Pneumococcal Disease Epidemiology
  • Reservoir Human carriers
  • Transmission Respiratory
    Autoinoculation
  • Temporal pattern Winter and early spring
  • Communicability Unknown
    Probably as long as organism in
    respiratory secretions

13
  • Invasive Pneumococcal Disease
  • Incidence by Age Group, 1998 and 2002

Rate per 100,000 population Source Active
Bacterial Core Surveillance/EIP Network
14
Direct Benefit of Vaccination Invasive
Pneumococcal Disease (IPD) Among Children Younger
Than 5 Years of Age
Rate/100,000 children younger than 5 years
Before vaccine 100 80
2006 24 0.5
All IPD Vaccine serotypes
Source Active Bacterial Core Surveillance/EIP
Network
15
Direct Effect of Vaccination Invasive
Pneumococcal Disease Among Children lt5 Years of
Age, 1998/99-2006
16
Rates of PCV7-type Invasive Pneumococcal Disease
among Adults, U.S., 1998/99-2006
2006 vs. baseline gt80 -90 (-93,-86) 65-79
-88 (-91,-83) 50-64 -84 (-87,-79) 18-49
-88 (-91,-86)
gt80 yrs
65-79 yrs
50-64 yrs
18-49 yrs
CDC, unpublished data 2008
17
Conditions That Increase Risk for Invasive
Pneumococcal Disease
  • Decreased immune function
  • Asplenia (functional or anatomic)
  • Chronic heart, pulmonary, liver or renal disease
  • Cigarette smoking
  • Cerebrospinal fluid (CSF) leak

18
Children at Increased Risk of Invasive
Pneumococcal Disease
  • Functional or anatomic asplenia, especially
    sickle cell disease
  • HIV infection
  • Recipient of cochlear implant
  • Out-of-home group child care
  • African American children
  • Alaska Native and American Indian children who
    live in Alaska, Arizona, or New Mexico
  • Navaho children who live in Colorado and Utah

19
Pneumococcal Disease Outbreaks
  • Outbreaks not common
  • Generally occur in crowded environments (jails,
    nursing homes)
  • Persons with invasive disease often have
    underlying illness
  • May have high fatality rate

20
Pneumococcal Vaccines
  • 1977 14-valent polysaccharide vaccine
    licensed
  • 1983 23-valent polysaccharide vaccine
    licensed (PPV23)
  • 2000 7-valent polysaccharide conjugate
    vaccine licensed (PCV7)

21
Pneumococcal Polysaccharide Vaccine
  • Purified capsular polysaccharide antigen from 23
    types of pneumococcus
  • Account for 88 of bacteremic pneumococcal
    disease
  • Cross-react with types causing additional 8 of
    disease

22
Pneumococcal Conjugate Vaccine
  • Pneumococcal polysaccharide conjugated to
    nontoxic diphtheria toxin (7 serotypes)
  • Vaccine serotypes account for 86 of bacteremia
    and 83 of meningitis among children younger than
    6 years of age

23
Pneumococcal Polysaccharide Vaccine
  • Not effective in children younger than 2 years
  • 60-70 against invasive disease
  • Less effective in preventing pneumococcal
    pneumonia

24
Pneumococcal Conjugate Vaccine
  • Highly immunogenic in infants and young children,
    including those with high-risk medical conditions
  • 97 effective against invasive disease caused by
    vaccine serotypes
  • 73 effective against pneumonia
  • 7 reduction in all episodes of acute otitis media

25
Pneumococcal Polysaccharide Vaccine
Recommendations
  • Adults 65 years and older
  • Persons 2 years and older with
  • chronic illness
  • anatomic or functional asplenia
  • immunocompromised (disease, chemotherapy,
    steroids)
  • HIV infection
  • environments or settings with increased risk

MMWR 199746(RR-8)1-24
26
Pneumococcal Conjugate Vaccine Recommendations
  • All children 24 months of age
  • Unvaccinated children 24-59 months with a
    high-risk medical condition

MMWR 200049(RR-9)1-35
27
Pneumococcal Conjugate Vaccine Recommendations
  • Doses at 2, 4, 6, months of age, booster dose at
    12-15 months of age
  • First dose as early as 6 weeks
  • Minimum interval of 4 weeks between first 3 doses
  • At least 8 weeks between dose 3 and dose 4
  • Unvaccinated children 7 months of age or older
    require fewer doses

MMWR 200049(RR-9)1-35
28
  • Pneumococcal Conjugate Vaccine
  • Schedule for Unvaccinated Older Children

separated by at least 8 weeks MMWR
200049(RR-9)1-35
29
  • Pneumococcal Conjugate Vaccine
  • for Children 24-59 Months of Age with a Lapsed
    Immunization Schedule

Previous Vaccination Any incomplete schedule 3
doses Fewer than 3 doses
No. of Doses Recommended 1 1 2
Group Healthy Increase risk
due to underlying medical condition separated
by at least 8 weeks MMWR 200757(No. 13)343-4
30
Pneumococcal Conjugate Vaccine
  • Children aged 24-59 months at high risk and
    previously vaccinated with PPV23 should receive 2
    doses of PCV7
  • Children at high risk who previously received
    PCV7 should receive PPV23 at 2 years of age or
    older

separated by at least 8 weeks MMWR
200049(RR-9)1-35
31
Pneumococcal Polysaccharide Vaccine Revaccination
  • Routine revaccination of immuno-competent persons
    is not recommended
  • Revaccination recommended for persons 2 years of
    age or older who are at highest risk of serious
    pneumococcal infection
  • Single revaccination dose at least 5 years after
    the first dose

MMWR 199746(RR-8)1-24
32
Pneumococcal Polysaccharide VaccineCandidates
for Revaccination
  • Persons 2 years of age or older with
  • functional or anatomic asplenia
  • immunosuppression
  • transplant
  • chronic renal failure
  • nephrotic syndrome
  • Persons vaccinated at younger than 65 years of
    age (at least 5 years since first dose)

MMWR 199746(RR-8)1-24
33
Pneumococcal Vaccines Adverse Reactions
  • Local reactions
  • polysaccharide 30-50
  • conjugate 10-20
  • Fever, myalgia
  • polysaccharide lt1
  • conjugate 15-24
  • Severe adverse rarereactions

34
Pneumococcal VaccinesContraindications and
Precautions
  • Severe allergic reaction to vaccine component or
    following prior dose of vaccine
  • Moderate or severe acute illness

35
Pneumococcal Polysaccharide Vaccine Coverage
  • Healthy People 2010 goal 90 coverage for
    persons gt65 years
  • 2003 BRFSS 64 of persons gt65 years of age ever
    vaccinated
  • Vaccination coverage levels were lower among
    persons 18-64 years of age with a chronic illness

36
Pneumococcal Polysaccharide VaccineMissed
Opportunities
  • gt65 of patients with severe pneumococcal disease
    had been hospitalized within preceding 3-5 years
    yet few had received vaccine
  • May be administered simultaneously with influenza
    vaccine

37
CDC Vaccines and ImmunizationContact Information
  • Telephone 800.CDC.INFO
  • Email nipinfo_at_cdc.gov
  • Website www.cdc.gov/vaccines
Write a Comment
User Comments (0)
About PowerShow.com